Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma
NCT07898813Phase 1Not yet recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2027
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of daraxonrasib in pancreatic ductal adenocarcinoma (PDAC) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Successful Receipt of Surgery Rate at 12 weeks. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07898813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898813.